1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. ADC Payload

ADC Cytotoxin

ADC payloads are cytotoxic agents that induce target cell death in Antibody Drug Conjugates (ADCs). An ADC is a targeted agent composed with a monoclonal antibody, a linker and a payload. The payload is the most important component as it determines the potency to kill cancer cells of an ADC.

There are many payloads which are currently being used such as Calicheamicins, Duocarmycins, Pyrrolobenzodiazepines (PBDs), Camptothecins, Daunorubicins/Doxorubicins, Auristatins and Maytansinoids. They can be divided in two classes based on their mechanism of action, DNA damaging agents and tubulin inhibitors. Among them Calicheamicins, Duocarmycins and PBDs are DNA minor grove binders, Camptothecins and Daunorubicins/Doxorubicins are topoisomerase inhibitors, which are DNA damaging agents. Auristatins and Maytansinoids are tubulin inhibitors.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-42487B
    (R)-Exatecan Intermediate 1
    99.95%
    (R)-Exatecan Intermediate 1 is an isomer of Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631), a camptothecin-based anticancer agent. Exatecan inhibits tumor growth by interfering with the proliferation and division of tumor cells by interacting with DNA. Exatecan is primarily used in research into a variety of cancers including ovarian, lung and breast cancer.
    (R)-Exatecan Intermediate 1
  • HY-79256
    MMAF-OMe
    99.62%
    MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively.
    MMAF-OMe
  • HY-12456
    Duocarmycin SA
    99.89%
    Duocarmycin SA is an orally active antitumor antibiotic with an IC50 of 10 pM. Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro.
    Duocarmycin SA
  • HY-101160
    SG2057
    99.93%
    SG2057 (DRG16) is a PBD dimer containing a pentyldioxy linkage which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts. SG2057 is a highly active antitumor agent.
    SG2057
  • HY-148424
    PBD dimer-2
    98.01%
    PBD dimer-2 (compound 2c) is a C8-linked pyrrolobenzodiazepine dimer. PBD dimer-2 can span an extra base pair and cross-link the 5′-Pu-GA(T/A)TC-Py sequence. PBD dimer-2 can be used as a payload for antibody–agent conjugates (ADCs), and it can be used for the research of cancer.
    PBD dimer-2
  • HY-161252
    PBD-monoamide
    PBD-monoamide, a modified PBD (pyrrolobenzodiazepine) dimer, is an ADC Cytotoxin. PBD-monoamide can be used for synthesis of DHES0815A (an HER2 ADC). PBD-monoamide has DNA-binding activity and reduces cell viability.
    PBD-monoamide
  • HY-131974
    Glucocorticoid receptor agonist-1
    99.80%
    Glucocorticoid receptor agonist-1 is a potent glucocorticoid receptor agonist with an IC50 of 2.8 nM extracted from patent WO2017210471A1, compound 41.
    Glucocorticoid receptor agonist-1
  • HY-148819
    NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
    98.71%
    NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (compound I) is a topoisomerase I inhibitor, which can be delivered to cells through conjugated antibody targeting, and has good ADC activity in vivo and in vitro.
    NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
  • HY-107769
    Duocarmycin TM
    99.82%
    Duocarmycin TM (CBI-TMI) is a potent antitumor antibiotic. Duocarmycin TM induces a sequence-selective alkylation of duplex DNA.
    Duocarmycin TM
  • HY-79490
    Ac-Exatecan
    99.02%
    Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC50 = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells.
    Ac-Exatecan
  • HY-132162
    7-MAD-MDCPT
    98.80%
    7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).
    7-MAD-MDCPT
  • HY-45171
    Exatecan intermediate 12
    Control 98.17%
    Exatecan intermediate 12 is an intermediate for the synthesis of ADC toxin Exatecan (HY-13631) and can be used to prepare ADC compounds.
    Exatecan intermediate 12
  • HY-125586
    β-Amanitin
    β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs).
    β-Amanitin
  • HY-15584
    Taltobulin
    99.90%
    Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis.
    Taltobulin
  • HY-B0015S
    Paclitaxel-d5
    98.13%
    Paclitaxel-d5 is a deuterium-labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization.
    Paclitaxel-d<sub>5</sub>
  • HY-133736
    PROTAC BRD4 Degrader-5-CO-PEG3-N3
    99.73%
    PROTAC BRD4 Degrader-5-CO-PEG3-N3 (Compound 2) is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader GNE-987 and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    PROTAC BRD4 Degrader-5-CO-PEG3-N3
  • HY-15162G
    Monomethyl auristatin E (GMP)
    Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor.
    Monomethyl auristatin E (GMP)
  • HY-15995
    Tubulysin A
    99.08%
    Tubulysin A (TubA) is an anticancer and antiangiogenic agent with anti-microtubule, anti-mitosis and anti-proliferative activity against a variety of cancer cells with IC50 values in the pmol range. It can induce apoptosis of cancer cells and has no effect on normal cells. Tubulysins are a group of potent cytotoxins consisting of nine members (A-I). Tubulysin A can synthesize ADC as ADC Cytotoxin.
    Tubulysin A
  • HY-156617A
    (αR)-Cyclopropaneacetamide-Exatecan
    99.93%
    (αR)-Cyclopropaneacetamide-Exatecan (compound 2-A), an Exenotecan derivative, is a cytotoxic agent. (αR)-Cyclopropaneacetamide-Exatecan inhibits U87MG and SK-BR-3 cells proliferation, with IC50s of 8.11 and 2.31 μM.
    (αR)-Cyclopropaneacetamide-Exatecan
  • HY-160885A
    NH2-Gly-PAB-Exatecan-D-glucuronic acid formic
    99.34%
    NH2-Gly-PAB-Exatecan-D-glucuronic acid formic (Compound 8) is the formic salt form of H2N-Gly-PAB-Exatecan-D-glucuronic acid. H2N-Gly-PAB-Exatecan-D-glucuronic acid formic is an intermediate, which reacts with NHS group to form drug-linker conjugate for ADC, Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179).
    NH2-Gly-PAB-Exatecan-D-glucuronic acid formic
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.